BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37114528)

  • 1. Gene expression profiling of peripheral blood mononuclear cells from women with cervical lesions reveals new markers of cancer.
    Ndiaye M; Diop G; Derbois C; Spadoni JL; Noirel J; Medina-Santos R; Coulonges C; Torres M; Dieye A; Sembene M; Deleuze JF; Toledano A; Dem A; Zagury JF; Le Clerc S
    Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37114528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China.
    Xiao M; Xu Q; Li H; Gao H; Bie Y; Zhang Z
    Medicine (Baltimore); 2016 Jan; 95(3):e2555. PubMed ID: 26817906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA Biomarkers of High-Grade Cervical Intraepithelial Neoplasia in Liquid Biopsy.
    Causin RL; da Silva LS; Evangelista AF; Leal LF; Souza KCB; Pessôa-Pereira D; Matsushita GM; Reis RM; Fregnani JHTG; Marques MMC
    Biomed Res Int; 2021; 2021():6650966. PubMed ID: 33954190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer.
    Espinosa AM; Alfaro A; Roman-Basaure E; Guardado-Estrada M; Palma Í; Serralde C; Medina I; Juárez E; Bermúdez M; Márquez E; Borges-Ibáñez M; Muñoz-Cortez S; Alcántara-Vázquez A; Alonso P; Curiel-Valdez J; Kofman S; Villegas N; Berumen J
    PLoS One; 2013; 8(2):e55975. PubMed ID: 23405241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.
    Syrjänen K
    Eur J Gynaecol Oncol; 2008; 29(3):205-21. PubMed ID: 18592782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating Diagnostic Problems of CIN1 and CIN2 Associated With High-risk HPV by Combining the Novel Molecular Biomarker PanHPVE4 With P16INK4a.
    van Baars R; Griffin H; Wu Z; Soneji YJ; van de Sandt M; Arora R; van der Marel J; Ter Harmsel B; Jach R; Okon K; Huras H; Jenkins D; Quint W; Doorbar J
    Am J Surg Pathol; 2015 Nov; 39(11):1518-1528. PubMed ID: 26379150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Previous Papanicolaou and Hybrid Capture 2 human papillomavirus testing results of 5699 women with histologically diagnosed cervical intraepithelial neoplasia 2/3.
    Wu T; Chen X; Zheng B; Li J; Xie F; Ding X; Zeng Z; Zhao C
    J Am Soc Cytopathol; 2019; 8(4):206-211. PubMed ID: 31272603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
    Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
    J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical correlation of cervical cancer screening using Pap smear test.
    Sharif YH
    J Popul Ther Clin Pharmacol; 2022; 29(1):e1-e8. PubMed ID: 35686892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk stratification of cervical disease using detection of human papillomavirus (HPV) E4 protein and cellular MCM protein in clinical liquid based cytology samples.
    Stevenson A; Kavanagh K; Pan J; Stevenson L; Griffin H; Doorbar J; Scott E; Deeny M; Cuschieri K; Graham SV
    J Clin Virol; 2018 Nov; 108():19-25. PubMed ID: 30218891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus and Papanicolaou tests to screen for cervical cancer.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Johansson B; Forslund O; Hansson BG; Rylander E; Dillner J
    N Engl J Med; 2007 Oct; 357(16):1589-97. PubMed ID: 17942872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.
    Salmerón J; Lazcano-Ponce E; Lorincz A; Hernández M; Hernández P; Leyva A; Uribe M; Manzanares H; Antunez A; Carmona E; Ronnett BM; Sherman ME; Bishai D; Ferris D; Flores Y; Yunes E; Shah KV
    Cancer Causes Control; 2003 Aug; 14(6):505-12. PubMed ID: 12948281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide DNA methylation profiling identifies two novel genes in cervical neoplasia.
    El-Zein M; Cheishvili D; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Szyf M; Franco EL;
    Int J Cancer; 2020 Sep; 147(5):1264-1274. PubMed ID: 31983058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiRNA detection in cervical exfoliated cells for missed high-grade lesions in women with LSIL/CIN1 diagnosis after colposcopy-guided biopsy.
    Ye J; Cheng XD; Cheng B; Cheng YF; Chen XJ; Lu WG
    BMC Cancer; 2019 Jan; 19(1):112. PubMed ID: 30700264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic Network Analysis Using Exfoliative Cervical Cells Could Discriminate a Potential Risk of Progression to Cancer in HPV-related Cervical Lesions: A Pilot Study.
    Park NJ; Choi Y; Lee D; Park JY; Kim JM; Lee YH; Hong DG; Chong GO; Han HS
    Cancer Genomics Proteomics; 2023; 20(1):75-87. PubMed ID: 36581343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study.
    Branca M; Costa S; Mariani L; Sesti F; Agarossi A; di Carlo A; Galati M; Benedetto A; Ciotti M; Giorgi C; Criscuolo A; Valieri M; Favalli C; Paba P; Santini D; Piccione E; Alderisio M; De Nuzzo M; di Bonito L; Syrjänen K
    Eur J Gynaecol Oncol; 2004; 25(6):689-98. PubMed ID: 15597844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The majority of metachronous CIN1 and CIN3 lesions are caused by different human papillomavirus genotypes, indicating that the presence of CIN1 seems not to determine the risk for subsequent detection of CIN3.
    Litjens RJ; Van de Vijver KK; Hopman AH; Ummelen MI; Speel EJ; Sastrowijoto SH; Van Gorp T; Slangen BF; Kruitwagen RF; Krüse AJ
    Hum Pathol; 2014 Feb; 45(2):221-6. PubMed ID: 24439220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.
    Moscicki AB; Flowers L; Huchko MJ; Long ME; MacLaughlin KL; Murphy J; Spiryda LB; Gold MA
    J Low Genit Tract Dis; 2019 Apr; 23(2):87-101. PubMed ID: 30907775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.